CONCORD HC GP (02453) announced its annual results for the year ended December 31, 2025. Revenue reached RMB 460 million, representing a year-on-year increase of 18.4%. The loss attributable to company owners was RMB 257 million, narrowing by 42.1% compared to the previous year. The basic loss per share was RMB 0.34. During the period, revenue from the hospital business increased by 37.4% year-on-year to RMB 373.3 million in 2025, primarily driven by significant growth in revenue from the proton therapy business at the Guangzhou hospital.